Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The <scp>EMBRACE</scp> study
Findings from the EMBRACE study demonstrated that treatment with erenumab in patients with high-frequency episodic migraine can provide positive therapeutic effects on ictal burden and pain, with residual migraine attacks tending to be shorter and less painful, with less overall impact.
Authors
- Yukun Zhu (ORCID: https://orcid.org/0000-0003-3838-0283)
- Gyöngyi Szabó (ORCID: https://orcid.org/0000-0003-0836-2527)
- Gabriel Paiva da Silva Lima (ORCID: https://orcid.org/0000-0001-8073-719X)
- Denise E. Chou (ORCID: https://orcid.org/0000-0002-6540-495X)
- Cristina Tassorelli (ORCID: https://orcid.org/0000-0003-1513-2113)
- Marcin Nastaj
- David W. Dodick (ORCID: https://orcid.org/0000-0002-9486-6790)
- Ani C. Khodavirdi
- Mahan Chehrenama
- Ajay Bhatia
- Renata Rao
- Sebastian Szklener
Institutions
- Obuda University (HU)
- Amgen (United States) (US)
- University of Pavia (IT)
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- M&I/Partners (NL)
- Mayo Clinic in Arizona (US)
- Lublin Oncology Center (PL)
- National Healthcare Service Center (HU)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1111/head.15071
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen